This technology identifies Pregnancy Specific Glycoproteins (PSG) as antigens expressed in multiple types of cancer that may serve as targets for cancer immunotherapies.
Cancer cells evade immune surveillance by exploiting T-cell function, antigen presentation, immune tolerance, and immune-suppressive modulators. Immunotherapies can suppress tumor proliferation by mobilizing a patient’s immune system to recognize and eliminate tumor cells more efficiently. While immunotherapies have greatly improved outcomes for some patients, treatment response rates remain only 10 to 50% depending on the type of cancer and therapeutic, highlighting the need for further improvement.
This technology determines Pregnancy Specific Glycoproteins (PSG) as potential immunotherapy targets against various cancers. These glycoproteins are not expressed in adult human tissues, but are present in more than 50% of tumors across different cancer types. Importantly, high levels of PSG are robustly correlated with worse survival rates, indicating that these proteins are likely mediators of immune tolerance in tumors. As such, targeting of PSG offers a potentially far-reaching immunotherapeutic strategy for the treatment of multiple types of cancer.
Patent Pending
IR CU20401
Licensing Contact: Ron Katz